Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» pamrevlumab
pamrevlumab
Duchenne muscular dystrophy: major trials and events to watch in 2023
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Flag link:
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Flag link:
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
CP Wire
FibroGen
pamrevlumab
IPF
idiopathic pulmonary fibrosis
Flag link:
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
FibroGen
pamrevlumab
idiopathic pulmonary fibrosis
Flag link:
